Brief: Medivir To Present Data At SITC 2022 Annual Meeting
08/09/2022 07:35
Sept 8 (Reuters) - Medivir AB MVIRb.ST :
* TO PRESENT DATA ON ADDITIVE EFFICACY OF FOSTROX IN
COMBINATION
WITH ANTI-PD1 IN NONCLINICAL TUMOR MODELS AT THE SITC 2022
ANNUAL MEETING
* ABSTRACT ABOUT ITS LEAD PROGRAM FOSTROXACITABINE
BRALPAMIDE
(FOSTROX) AND POTENTIAL EFFICACY IN PRIMARY LIVER CANCER HAS
BEEN ACCEPTED FOR PRESENTATION AT AT SITC 37TH ANNUAL MEETING,
HELD NOVEMBER 10-12, 2022, IN BOSTON, USA
Source text for Eikon: ID:nWkr8l3lZS
Further company coverage: MVIRb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))